Relmada Therapeutics to Present at Jefferies London Healthcare Conference
Rhea-AI Summary
Relmada Therapeutics (Nasdaq: RLMD), a late-stage biotechnology company focusing on central nervous system diseases, has announced its participation in the Jefferies London Healthcare Conference. CEO Sergio Traversa will present on Wednesday, November 20, 2024, at 12:00 PM GMT. The presentation will be available via webcast, with a replay accessible on Relmada's website investor page for 90 days after the conference.
Positive
- None.
Negative
- None.
News Market Reaction
On the day this news was published, RLMD declined 1.32%, reflecting a mild negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
Conference being held November 19-21, 2024
CORAL GABLES, Fla., Nov. 19, 2024 (GLOBE NEWSWIRE) -- Relmada Therapeutics, Inc. (Nasdaq: RLMD, “Relmada”, “the Company”), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today announced that Sergio Traversa, Chief Executive Officer (CEO), will present at the Jefferies London Healthcare Conference on Wednesday, November 20, 2024.
Jefferies London Healthcare Conference details:
| Presentation: | Wednesday, November 20, 2024 at 12:00 PM GMT |
| Speaker: | Sergio Traversa, CEO |
| Registration: | Webcast link |
The replay of the webcast will be available on the “For Investors/Events” page of the Relmada website for 90 days following the conference.
About Relmada Therapeutics, Inc.
Relmada Therapeutics is a late-stage biotechnology company addressing diseases of the central nervous system (CNS), with a focus on major depressive disorder (MDD). Relmada's experienced and dedicated team is committed to making a difference in the lives of patients and their families. Relmada's lead program, REL-1017, is a new chemical entity (NCE) and novel NMDA receptor (NMDAR) channel blocker that preferentially targets hyperactive channels while maintaining physiological glutamatergic neurotransmission. REL-1017 is in late-stage development as an adjunctive treatment for MDD in adults. The Company is also developing REL-P11, a proprietary low-dose psilocybin, as an investigational agent for metabolic disease. Learn more at www.relmada.com.
Investor Contact:
Tim McCarthy
LifeSci Advisors
Tim@LifeSciAdvisors.com
Media Inquiries:
Corporate Communications
media@relmada.com
FAQ
When is Relmada Therapeutics (RLMD) presenting at the Jefferies London Healthcare Conference 2024?
How long will the Relmada Therapeutics (RLMD) Jefferies conference presentation replay be available?
What type of company is Relmada Therapeutics (RLMD) according to the announcement?
Where can investors access the replay of Relmada's (RLMD) Jefferies conference presentation?
